# Highlights of This Issue 1689

## REVIEW

1691  
BH3 Mimetics: Status of the Field and New Developments  
Christian Billard

## SMALL MOLECULE THERAPEUTICS

1701  
Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma  
Nicholas J. Andersen, Brian J. Nickoloff, Karl J. Dykema, Elissa A. Boguslawski, Roman I. Krivochenitsiner, Roe E. Froman, Michelle J. Dawes, Laurence H. Baker, Dafydd G. Thomas, Debra A. Kamstock, Barbara E. Kitchell, Kyle A. Furge, and Nicholas S. Duesbery

1715  
AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo  

## LARGE MOLECULE THERAPEUTICS

1728  
Smac Mimetics in Combination with TRAIL Selectively Target Cancer Stem Cells in Nasopharyngeal Carcinoma  
Man-si Wu, Guang-feng Wang, Zhi-qiang Zhao, Yi Liang, Heng-bang Wang, Mao-yi Wu, Ping Min, Li-zhen Chen, Qi-sheng Feng, Jin-xin Bei, Yi-xin Zeng, and Dajun Yang

1738  
Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies  

## CANCER THERAPEUTICS INSIGHTS

1749  
S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab  
Mike F. Burbridge, Céline J. Bossard, Carine Saunier, Imre Fejes, Alain Bruno, Stéphane Léonce, Gilles Ferry, Georges Da Violante, François Bouzom, Valérie Cattan, Anne Jacquet-Bescoud, Paolo M. Comoglio, Brian P. Lockhart, Jean A. Boutin, Alex Cordi, Jean-Claude Ortuño, Alain Pierré, John A. Hickman, Francisco H. Cruzalegui, and Stéphane Depil

1763  
Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro  
Jinsong Hu, Els Van Valkenborgh, Dehui Xu, Eline Menu, Hendrik De Raeye, Elke De Bryune, Song Xu, Ben Van Camp, Damian Handisides, Charles P. Hart, and Karin Vanderkerken

1774  
Targeted Cytolysins Synergistically Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin  
Christopher M. Pirie, David V. Liu, and K. Dane Wittrup

1783  
Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells  

1796  
Cyclin G1 Expands Liver Tumor-Initiating Cells by Sox2 Induction via Akt/mTOR Signaling  
Wen Wen, Tao Han, Cheng Chen, Lei Huang, Wen Sun, Xue Wang, Shu-Zhen Chen, Dai-Min Xiang, Liang Tang, Dan Cao, Gen-Sheng Feng, Meng-Chao Wu, Jin Ding, and Hong-Yang Wang
An Autocrine Loop between TGF-β1 and the Transcription Factor Brachyury Controls the Transition of Human Carcinoma Cells into a Mesenchymal Phenotype
Cecilia Larocca, Joseph R. Cohen, Romaine I. Fernando, Bruce Huang, Duane H. Hamilton, and Claudia Palena

Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect
Bart S. Hendriks, Stephan G. Klinz, Joseph G. Reynolds, Christopher W. Espelin, Daniel F. Gaddy, and Thomas J. Wickham

Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer
Yezli Zhu, Chengfei Liu, Nagalakshmi Nadiminty, Wei Lou, Ramakumar Tummala, Christopher P. Evans, and Allen C. Gao

Ethacrynic Acid Oxadiazole Analogs Induce Apoptosis in Malignant Hematologic Cells through Downregulation of Mcl-1 and c-FLIP, Which Was Attenuated by GSTP1-1
Guyue Liu, Rui Wang, Yueting Wang, Pengzhan Li, Guisen Zhao, Lixiang Zhao, and Yongkui Jing

Sulindac Selectively Inhibits Colon Tumor Cell Growth by Activating the cGMP/PKG Pathway to Suppress Wnt/β-Catenin Signaling
Nan Li, Yaguang Xi, Heather N. Tinsley, Evrim Gurpinar, Bernard D. Gary, Bing Zhu, Yonghe Li, Xi Chen, Adam B. Keeton, Ashraf H. Abadi, Mary P. Moyer, William E. Grizzle, Sanjiv S. Gambhir

Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53
Mayur A. Gadhiyar, Maria Rita Sciuto, Marcus Vinicius Ortega Alves, Curtis R. Pickering, Abdullaah A. Osman, David M. Neskey, Mei Zhao, Alison L. Fitzgerald, Jeffrey N. Myers, and Mitchell J. Frederick

BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer

Apoptotic Circulating Tumor Cells in Early and Metastatic Breast Cancer Patients
Galatea Kallergi, Georgios Konstantinidis, Harris Markomanolaki, Maria A. Papadaki, Dimitris Mavroudis, Christos Stournaras, Vassilis Georgoulis, and Sofia Agelaki

A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide
Hua Fan-Minogue, Sandhya Bodapati, David Solow-Cordero, Alice Fan, Ramasamy Paulmurugan, Tarik F. Massoud, Dean W. Felsher, and Sanjiv S. Gambhir

NF1 Deletion Generates Multiple Subtypes of Soft-Tissue Sarcoma That Respond to MEK Inhibition
Rebecca D. Dodd, Jeffrey K. Mito, William C. Eward, Rhea Chitalia, Mohit Sachdeva, Yan Ma, Jordi Barretina, Leslie Dodd, and David G. Kirsch

Correction: MPT0B098, a Novel Microtubule Inhibitor That Destabilizes the Hypoxia-Inducible Factor-1α mRNA through Decreasing Nuclear–Cytoplasmic Translocation of RNA-Binding Protein HuR

O. Michael Colvin, MD: In Memoriam (1936–2013)

Correction: COMPANION DIAGNOSTICS AND BIOMARKERS

OBITUARY

CORRECTIONS
Correction: Dual Programmed Cell Death Pathways Induced by p53 Transactivation Overcome Resistance to Oncolytic Adenovirus in Human Osteosarcoma Cells

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org

ABOUT THE COVER

Continued androgen receptor (AR) expression and signaling is a key driver in castration-resistant prostate cancer (CRPC). AZD3514 is an orally bioavailable drug that inhibits androgen-dependent and -independent AR signalling in vitro and in vivo. Using immunohistochemistry, R3327H prostate tumors were scored for intensity of nuclear AR to assess the impact of AZD3514 on AR. For more details, see article by Loddick and colleagues on page 1715.
Molecular Cancer Therapeutics

12 (9)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/12/9

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.